Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ruling Against Hi-Tech Pharmaceuticals Spotlights FTC Strategies

This article was originally published in The Tan Sheet

Executive Summary

A recent court ruling emphasizes Federal Trade Commission strategies to prevent companies from repeatedly making false claims, stretching substantiation data, using deceptive endorsements and creating shell businesses

You may also be interested in...



Hi-Tech CEO Could Face Jail For Violating Court Order To Recall Weight Loss Products

A federal judge soon will decide whether Hi-Tech Pharmaceuticals CEO Jared Wheat goes to jail for failing to recall weight loss products marketed with false claims. Wheat has a history of run-ins with FDA, FTC and DEA for marketing supplements adulterated with drugs and making false claims for products.

Hi-Tech CEO Could Face Jail For Violating Court Order To Recall Weight Loss Products

A federal judge soon will decide whether Hi-Tech Pharmaceuticals CEO Jared Wheat goes to jail for failing to recall weight loss products marketed with false claims. Wheat has a history of run-ins with FDA, FTC and DEA for marketing supplements adulterated with drugs and making false claims for products.

In Brief

Hi-Tech OTC sales fall; social media posts prompt FDA warning; FDA warns PruTect Rx about claims; study finds no DMAA in geranium oil; prebiotic recall spreads to Eco Health product; more news In Brief.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS101776

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel